Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinib

Ambrus Gángó, Donát Alpár, Bence Galik, Dóra Marosvári, Richárd Kiss, Viktória Fésüs, Dóra Aczél, Ediz Eyüpoglu, Noémi Nagy, Ákos Nagy, Szilvia Krizsán, Lilla Reiniger, Péter Farkas, András Kozma, Emma Ádám, Szabolcs Tasnády, Marienn Réti, A. Matolcsy, Attila Gyenesei, Zoltán Mátrai & 1 others Csaba Bödör

Research output: Contribution to journalArticle

Abstract

The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib is inducing durable responses in chronic lymphocytic leukemia (CLL) patients with refractory/relapsed disease or with TP53 defect, with BTK and phospholipase C gamma 2 (PLCG2) mutations representing the predominant mechanisms conferring secondary ibrutinib resistance. To understand the landscape of genomic changes and the dynamics of subclonal architecture associated with ibrutinib treatment, an ultra-deep next-generation sequencing analysis of 30 recurrently mutated genes was performed on sequential samples of 20 patients, collected before and during single-agent ibrutinib treatment. Mutations in the SF3B1, MGAand BIRC3 genes were enriched during ibrutinib treatment, while aberrations in the BTK, PLCG2, RIPK1, NFKBIE and XPO1 genes were exclusively detected in posttreatment samples. Besides the canonical mutations, four novel BTK mutations and three previously unreported PLCG2 variants were identified. BTK and PLCG2 mutations were backtracked in five patients using digital droplet PCR and were detectable on average 10.5 months before clinical relapse. With a median follow-up time of 36.5 months, 7/9 patients harboring BTK mutations showed disease progression based on clinical and/or laboratory features. In conclusion, subclonal heterogeneity, dynamic clonal selection and various patterns of clonal variegation were identified with novel resistance-associated BTK mutations in individual patients treated with ibrutinib.

Original languageEnglish
JournalInternational Journal of Cancer
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Dissection
Phospholipase C gamma
Mutation
Genes
Agammaglobulinaemia tyrosine kinase
PCI 32765
Disease Progression
Therapeutics
Recurrence
Polymerase Chain Reaction

Keywords

  • chronic lymphocytic leukemia
  • clonal evolution
  • ibrutinib
  • precision medicine
  • targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinib. / Gángó, Ambrus; Alpár, Donát; Galik, Bence; Marosvári, Dóra; Kiss, Richárd; Fésüs, Viktória; Aczél, Dóra; Eyüpoglu, Ediz; Nagy, Noémi; Nagy, Ákos; Krizsán, Szilvia; Reiniger, Lilla; Farkas, Péter; Kozma, András; Ádám, Emma; Tasnády, Szabolcs; Réti, Marienn; Matolcsy, A.; Gyenesei, Attila; Mátrai, Zoltán; Bödör, Csaba.

In: International Journal of Cancer, 01.01.2019.

Research output: Contribution to journalArticle

Gángó, A, Alpár, D, Galik, B, Marosvári, D, Kiss, R, Fésüs, V, Aczél, D, Eyüpoglu, E, Nagy, N, Nagy, Á, Krizsán, S, Reiniger, L, Farkas, P, Kozma, A, Ádám, E, Tasnády, S, Réti, M, Matolcsy, A, Gyenesei, A, Mátrai, Z & Bödör, C 2019, 'Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinib', International Journal of Cancer. https://doi.org/10.1002/ijc.32502
Gángó, Ambrus ; Alpár, Donát ; Galik, Bence ; Marosvári, Dóra ; Kiss, Richárd ; Fésüs, Viktória ; Aczél, Dóra ; Eyüpoglu, Ediz ; Nagy, Noémi ; Nagy, Ákos ; Krizsán, Szilvia ; Reiniger, Lilla ; Farkas, Péter ; Kozma, András ; Ádám, Emma ; Tasnády, Szabolcs ; Réti, Marienn ; Matolcsy, A. ; Gyenesei, Attila ; Mátrai, Zoltán ; Bödör, Csaba. / Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinib. In: International Journal of Cancer. 2019.
@article{f387c5fbc8dd411e9ccae29806b8aa51,
title = "Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinib",
abstract = "The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib is inducing durable responses in chronic lymphocytic leukemia (CLL) patients with refractory/relapsed disease or with TP53 defect, with BTK and phospholipase C gamma 2 (PLCG2) mutations representing the predominant mechanisms conferring secondary ibrutinib resistance. To understand the landscape of genomic changes and the dynamics of subclonal architecture associated with ibrutinib treatment, an ultra-deep next-generation sequencing analysis of 30 recurrently mutated genes was performed on sequential samples of 20 patients, collected before and during single-agent ibrutinib treatment. Mutations in the SF3B1, MGAand BIRC3 genes were enriched during ibrutinib treatment, while aberrations in the BTK, PLCG2, RIPK1, NFKBIE and XPO1 genes were exclusively detected in posttreatment samples. Besides the canonical mutations, four novel BTK mutations and three previously unreported PLCG2 variants were identified. BTK and PLCG2 mutations were backtracked in five patients using digital droplet PCR and were detectable on average 10.5 months before clinical relapse. With a median follow-up time of 36.5 months, 7/9 patients harboring BTK mutations showed disease progression based on clinical and/or laboratory features. In conclusion, subclonal heterogeneity, dynamic clonal selection and various patterns of clonal variegation were identified with novel resistance-associated BTK mutations in individual patients treated with ibrutinib.",
keywords = "chronic lymphocytic leukemia, clonal evolution, ibrutinib, precision medicine, targeted therapy",
author = "Ambrus G{\'a}ng{\'o} and Don{\'a}t Alp{\'a}r and Bence Galik and D{\'o}ra Marosv{\'a}ri and Rich{\'a}rd Kiss and Vikt{\'o}ria F{\'e}s{\"u}s and D{\'o}ra Acz{\'e}l and Ediz Ey{\"u}poglu and No{\'e}mi Nagy and {\'A}kos Nagy and Szilvia Krizs{\'a}n and Lilla Reiniger and P{\'e}ter Farkas and Andr{\'a}s Kozma and Emma {\'A}d{\'a}m and Szabolcs Tasn{\'a}dy and Marienn R{\'e}ti and A. Matolcsy and Attila Gyenesei and Zolt{\'a}n M{\'a}trai and Csaba B{\"o}d{\"o}r",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/ijc.32502",
language = "English",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinib

AU - Gángó, Ambrus

AU - Alpár, Donát

AU - Galik, Bence

AU - Marosvári, Dóra

AU - Kiss, Richárd

AU - Fésüs, Viktória

AU - Aczél, Dóra

AU - Eyüpoglu, Ediz

AU - Nagy, Noémi

AU - Nagy, Ákos

AU - Krizsán, Szilvia

AU - Reiniger, Lilla

AU - Farkas, Péter

AU - Kozma, András

AU - Ádám, Emma

AU - Tasnády, Szabolcs

AU - Réti, Marienn

AU - Matolcsy, A.

AU - Gyenesei, Attila

AU - Mátrai, Zoltán

AU - Bödör, Csaba

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib is inducing durable responses in chronic lymphocytic leukemia (CLL) patients with refractory/relapsed disease or with TP53 defect, with BTK and phospholipase C gamma 2 (PLCG2) mutations representing the predominant mechanisms conferring secondary ibrutinib resistance. To understand the landscape of genomic changes and the dynamics of subclonal architecture associated with ibrutinib treatment, an ultra-deep next-generation sequencing analysis of 30 recurrently mutated genes was performed on sequential samples of 20 patients, collected before and during single-agent ibrutinib treatment. Mutations in the SF3B1, MGAand BIRC3 genes were enriched during ibrutinib treatment, while aberrations in the BTK, PLCG2, RIPK1, NFKBIE and XPO1 genes were exclusively detected in posttreatment samples. Besides the canonical mutations, four novel BTK mutations and three previously unreported PLCG2 variants were identified. BTK and PLCG2 mutations were backtracked in five patients using digital droplet PCR and were detectable on average 10.5 months before clinical relapse. With a median follow-up time of 36.5 months, 7/9 patients harboring BTK mutations showed disease progression based on clinical and/or laboratory features. In conclusion, subclonal heterogeneity, dynamic clonal selection and various patterns of clonal variegation were identified with novel resistance-associated BTK mutations in individual patients treated with ibrutinib.

AB - The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib is inducing durable responses in chronic lymphocytic leukemia (CLL) patients with refractory/relapsed disease or with TP53 defect, with BTK and phospholipase C gamma 2 (PLCG2) mutations representing the predominant mechanisms conferring secondary ibrutinib resistance. To understand the landscape of genomic changes and the dynamics of subclonal architecture associated with ibrutinib treatment, an ultra-deep next-generation sequencing analysis of 30 recurrently mutated genes was performed on sequential samples of 20 patients, collected before and during single-agent ibrutinib treatment. Mutations in the SF3B1, MGAand BIRC3 genes were enriched during ibrutinib treatment, while aberrations in the BTK, PLCG2, RIPK1, NFKBIE and XPO1 genes were exclusively detected in posttreatment samples. Besides the canonical mutations, four novel BTK mutations and three previously unreported PLCG2 variants were identified. BTK and PLCG2 mutations were backtracked in five patients using digital droplet PCR and were detectable on average 10.5 months before clinical relapse. With a median follow-up time of 36.5 months, 7/9 patients harboring BTK mutations showed disease progression based on clinical and/or laboratory features. In conclusion, subclonal heterogeneity, dynamic clonal selection and various patterns of clonal variegation were identified with novel resistance-associated BTK mutations in individual patients treated with ibrutinib.

KW - chronic lymphocytic leukemia

KW - clonal evolution

KW - ibrutinib

KW - precision medicine

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85068170987&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068170987&partnerID=8YFLogxK

U2 - 10.1002/ijc.32502

DO - 10.1002/ijc.32502

M3 - Article

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

ER -